Type
Closure
Country
Belgium
Region
Région wallonne; Prov. Hainaut; Arr. Charleroi
Location of affected unit(s)
Gosselies
Sector
Manufacturing
(20 - 21) Manufacture of chemicals and pharmaceuticals
21.2 - Manufacture of pharmaceutical preparations
21.2 - Manufacture of pharmaceutical preparations

150 jobs
Number of planned job losses
Job loss
Announcement Date
23 January 2026
Employment effect (start)
25 January 2026
Foreseen end date

Description

Catalent, an American biotechnology company, announced the closure of its Gosselies site in Belgium, where 150 workers will lose their jobs. The company, which has maintained a European production base there since 2020, will start the first phase of its redundancy plan in January 2026.

The shutdown follows a decline in production at the site and is part of the firm’s effort to streamline operations after two previous restructures in 2023: Catalent 2023 - BE and 2025. Unions are engaged in discussions and a cessation of activity or a partial takeover by other biotech companies is reportedly being discussed.


Sources

Citation

Eurofound (2026), Catalent, Closure in Belgium, factsheet number 204623, European Restructuring Monitor. Dublin, https://apps.eurofound.europa.eu/restructuring-events/detail/204623.